ArticleBMC infectious diseases2025
Characterization of antimicrobial resistance among Proteus mirabilis isolates from catheter-associated urinary tract infections and non-catheter-associated urinary tract infections in Egypt.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- The agroenvironmental-clinical link of Proteus mirabilis: Genomic epidemiology, clonal relationships, and shared resistance and virulence profiles.Folia microbiologica · 2026Article
- Inhibition of Proteus mirabilis growth through gallium-based disruption of iron and heme metabolism.The Journal of antibiotics · 2026Article
- Assessment of genetic determinants of virulence and fluoroquinolone resistance in Proteus mirabilis isolates from urinary tract infections in Egypt.BMC infectious diseases · 2026Article
- Pangenome analysis ofAntimicrobial agents and chemotherapy · 2026Article
- First experimentally characterised Proteus phage endolysins have distinct metal cofactor dependencies.Applied microbiology and biotechnology · 2026Article
- Biofilm Formation, Virulence-Associated Genes, and Antimicrobial Resistance inMicroorganisms · 2026Article
- Prevalence of ESBL producing uropathogens and associated risk factors in catheter associated urinary tract infections a cross-sectional study from Syria.BMC microbiology · 2026Article
- Isolation, Identification and Pathogenicity Analysis of Proteus mirabilis in Cynomolgus Monkey From Yunnan, China.Veterinary medicine and science · 2026Article
- A One Health Perspective onMicroorganisms · 2026Review
- Dissemination of integrons and carbapenemase-encoding genes among multidrug resistant Proteus mirabilis isolated from urinary tract infections in Egypt.BMC infectious diseases · 2026Article
- Epidemiological and antimicrobial resistance profile of catheter-associated and non-catheter urinary tract infections in trauma patients (2017-2024).BMC infectious diseases · 2025Article
- Molecular characterization of multidrug-resistantIranian journal of microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRecent worldwide reports of increased numbers of multidrug-resistant (MDR) Proteus mirabilis (P. mirabilis) isolates, particularly those producing extended-spectrum β-lactamases (ESBLs), are alarming. P. mirabilis is a common causative agent of complicated urinary tract infections (UTIs), particularly in patients with long-term urinary catheterization. This study aimed to assess the prevalence, antibiotic resistance patterns, and determinants of P. mirabilis among catheter-associated UTIs (CAUTI) and non-catheter-associated UTIs (non-CAUTI).
methodsOne hundred and three Proteus strains isolated from 613 UTI patients in Minia, Egypt, were examined for antibiotic resistance patterns, ESBL production, and sulphonamide resistance phenotypically. Class 1 and 2 integrons, ESBL, and sul resistance genes were detected by Polymerase chain reaction (PCR), followed by molecular typing of ESBL-producing isolates from catheterized UTI patients using ERIC-PCR.
resultsProteus isolates were detected in 20% of the UTIs, with a higher rate among inpatients (27.3%) compared to outpatients (10.6%). Proteus was more significantly isolated from catheterized UTI patients (28.2%, 55/195) than from non-catheterized patients (14.9%, 48/321). Of the 103 Proteus isolates, 99 (96.1%) were identified as P. mirabilis. High resistance was observed against trimethoprim/sulfamethoxazole (SXT) (80.6%), amoxicillin-clavulanic (AMC) (57.3%), ceftazidime (55.3%), and imipenem (46.6%) antibiotics. Significantly higher resistance rates were observed among Proteus isolates from inpatients and catheterized patients. Of the 103 Proteus strains, 81 (78.6%) were MDR, with 70.9% of the isolates from catheterized patients. About 74.6% of the isolates from inpatients were MDR. Sul genes were detected in 77 isolates (74.7%). The frequency of ESBL-producing Proteus isolates was 37.9% which was significantly higher in catheterized patients with increasing dissemination of bla
conclusionThe high frequency of MDR P. mirabilis strains isolated from UTIs in Egypt, particularly among catheterized patients, is a major concern, especially with disseminating class 1 and 2 integrons among isolates. The study also highlights the decreased susceptibility to sulphonamides, 3rd generation cephalosporins, and imipenem, commonly used to treat UTIs. Increased dissemination of ESBL-producing Proteus isolates among CAUTIs complicates their treatments. This important pathogen deserves more attention in the future for a better understanding of resistance mechanisms and the dissemination potential of resistant strains.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.